iTeos Therapeutics’ (ITOS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research report sent to investors on Friday,Benzinga reports. The firm currently has a $46.00 price target on the stock.

A number of other analysts have also weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $25.00 target price on shares of iTeos Therapeutics in a report on Tuesday. Wells Fargo & Company started coverage on shares of iTeos Therapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price for the company. Finally, JPMorgan Chase & Co. lowered their price objective on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Monday, August 12th.

iTeos Therapeutics Stock Down 2.7 %

Shares of iTeos Therapeutics stock traded down $0.23 during trading on Friday, reaching $8.23. 1,052,727 shares of the stock were exchanged, compared to its average volume of 442,983. The stock’s fifty day moving average is $10.27 and its 200 day moving average is $13.97. The firm has a market cap of $300.64 million, a price-to-earnings ratio of -2.61 and a beta of 1.39. iTeos Therapeutics has a 1 year low of $7.99 and a 1 year high of $18.75.

Institutional Investors Weigh In On iTeos Therapeutics

Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC bought a new position in iTeos Therapeutics in the 1st quarter worth about $3,337,000. Clearline Capital LP bought a new stake in shares of iTeos Therapeutics during the second quarter valued at approximately $2,328,000. Candriam S.C.A. purchased a new position in iTeos Therapeutics in the 2nd quarter worth approximately $7,558,000. Kennedy Capital Management LLC purchased a new position in iTeos Therapeutics in the 1st quarter worth approximately $1,988,000. Finally, Dimensional Fund Advisors LP raised its holdings in iTeos Therapeutics by 14.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 908,329 shares of the company’s stock worth $13,481,000 after acquiring an additional 117,159 shares during the last quarter. Institutional investors own 97.16% of the company’s stock.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.